REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Disaggregation of Revenue [Line Items]
Total net revenues	$ 227,813	$ 148,332	$ 636,306	$ 423,802
Rare Disease and Brands total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	129,125	65,621	340,365	187,456
Rare Disease total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	118,450	56,426	291,372	142,556
Cortrophin Gel
Disaggregation of Revenue [Line Items]
Total net revenues	101,850	52,555	236,347	138,685
ILUVIEN and YUTIQ
Disaggregation of Revenue [Line Items]
Total net revenues	16,600	3,871	55,025	3,871
Brands
Disaggregation of Revenue [Line Items]
Total net revenues	10,675	9,195	48,993	44,900
Generics and Other total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	98,688	82,711	295,941	236,346
Generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	94,375	78,223	283,350	222,404
Royalties and other pharmaceutical services
Disaggregation of Revenue [Line Items]
Total net revenues	$ 4,313	$ 4,488	$ 12,591	$ 13,942